- Home
- AZ vs ALLO Comparison
AZ vs ALLO Comparison
Compare AZ & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | ALLO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.5M | 252.9M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | AZ | ALLO |
|---|---|---|
| Price | $5.58 | $2.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $20.00 | $8.27 |
| AVG Volume (30 Days) | 440.0K | ★ 4.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,000.00 |
| Revenue This Year | $30.87 | N/A |
| Revenue Next Year | $480.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.00 | $0.86 |
| 52 Week High | $12.36 | $2.80 |
Technical Indicators
Market Signals| Indicator | AZ | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 65.34 |
| Support Level | $5.10 | $1.01 |
| Resistance Level | $6.63 | N/A |
| Average True Range (ATR) | 0.41 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 41.80 | 79.03 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.